Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

@article{Fumoleau2003RandomizedTC,
  title={Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.},
  author={Pierre Fumoleau and Pierre Kerbrat and Pascale Romestaing and Pierre Fargeot and Alain G. Br{\'e}mond and Mo{\"i}se Namer and Simon Schraub and M. J. Goudier and Jeanne Mihura and Alain M Monnier and Pierre Clav{\`e}re and Daniel Serin and Philippe Seffert and Christiane Pourny and Thomas Facchini and J. Ph. Jacquin and Jean-François Sztermer and Jean Datchary and Ren{\'e} Ramos and Elisabeth Luporsi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 2},
  pages={298-305}
}
PURPOSE To evaluate the duration and dose intensity of epirubicin-based regimens in premenopausal patients with lymph node-positive breast cancer. PATIENTS AND METHODS Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…